Much to the relief of Aussie investors, the S&P/ASX 200 Index (ASX: XJO) is having a much better session on Thursday. In afternoon trade, the benchmark index is up 0.5% to 7,819.2 points.

Four ASX shares that have failed to follow the market higher today are listed below. Here's why they are falling:

The A2 Milk share price is down almost 3% to $5.85. This is despite there being no news out of the infant formula company. However, it is possible that profit taking could be weighing on its shares today. After all, they remain up approximately 38% year to date despite this decline. Investors have been bidding the A2 Milk share price higher this year thanks to a stronger than expected performance in FY 2024. During the first half, A2 Milk reported a 3.7% increase in revenue to NZ$812.1 million and a 15.6% jump in net profit after tax to NZ$85.3 million.

The Lindsay Australia share price is down 2% to $1.03. This decline has been driven by the logistic services provider's shares going ex-dividend for its interim dividend. In February, Lindsay Australia released its half-year results and reported a 23.9% increase in operating revenue to a record of $417.9 million and a 21.7% jump in underlying EBITDA to a record of $52.1 million. This allowed the company's board to increase its interim dividend by 10.5% to a fully franked 2.1 cents per share. Eligible shareholders can now look forward to receiving this dividend later this month on April 19.

The Meridian Energy share price is down 2% to $5.47. Investors have been selling this energy company's shares despite there being no news out of it today. Though, given that utilities are generally regarded as safe haven assets, it's possible that some investors are dumping its shares today and moving back into risk assets after the market recovered from yesterday's selloff. Meridian Energy shares remain up 10% over the last 12 months.

The Opthea share price is down over 2.5% to 73 cents. This morning, this retinal disease focused global biopharmaceutical company released a presentation relating to its Sozinibercept product. Management believes it has the potential to be the first product in more than 15 years to improve visual outcomes. It is addressing a high unmet need for wet age-related macular degeneration (AMD). And while the company estimates that it has a multi-billion dollar commercial opportunity in a growing market, investors don't appear to be overly convinced based on its share price performance.